Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter Prices Notes Offering; Files for Common Stock Offering

NEW YORK (GenomeWeb News) – Beckman Coulter has priced two senior notes offerings and has filed a prospectus to sell up to $250 million worth of common stock, which will help pay for its $780 million acquisition of Olympus' diagnostics business.

The offerings were expected, as Beckman said in late February that it would pay for the acquisition through a combination of around $500 million worth of new debt and roughly $300 million of its common stock.

Today, Beckman said that it has priced $250 million worth of senior notes that mature in 2015 at a rate of 6 percent, and it priced $250 million worth of senior notes that mature in 2019 at a rate of 7 percent. The offerings are expected to close on May 21.

The firm also has filed a prospectus to raise $235 million, or $250 million if the underwriters exercise the over-allotment option, through the sale of common stock. The firm did not say when it expects to complete the common stock offering.

Beckman's purchase of the Olympus diagnostics business cleared US antitrust review by the Federal Trade Commission last week.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.